Skip to main content

Table 4 Base model ICER

From: An economic model of long-term use of celecoxib in patients with osteoarthritis

 

QALYs

Costs

ICER

nsNSAID

10.1678

$10,096

 

Celecoxib

10.2982

$14,151

 

Net incremental

0.1304

$4,055

$31,097

  1. ICER, incremental cost-effective ratio; QALY, quality-adjusted life year; nsNSAID, nonselective nonsteroidal anti-inflammatory drugs.
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us